Biogen | BIIB - Operating Profit


Biogen reported $659.6M in Operating Profit for its fiscal quarter ending in September of 2025.





Operating Profit Change Date
AbbVie USD 5.81B 1.23B Dec/2025
Acadia Pharmaceuticals USD 35.76M 3.38M Sep/2025
ALKERMES USD -10.95M 100.03M Dec/2025
Amgen USD 3.96B 464M Dec/2025
Bayer EUR -543M 556M Sep/2025
Biogen USD 659.6M 192.2M Sep/2025
BioMarin Pharmaceutical USD 198.39M 230.08M Dec/2025
Bristol-Myers Squibb USD 4.2B 562M Dec/2025
Eli Lilly USD 8.99B 599.9M Dec/2025
Esperion Therapeutics USD -16.03M 18.6M Sep/2024
Gilead Sciences USD 2.96B 551M Dec/2025
Incyte USD 383.88M 47.43M Dec/2025
Merck USD 6.24B 318M Dec/2025
Moderna USD -857M 597M Dec/2025
Neurocrine Biosciences USD 227.9M 11.4M Dec/2025
Novartis USD 4.5B 363M Sep/2025
Pfizer USD 4.65B 3.99B Dec/2025
PTC Therapeutics USD -81.62M 85.11M Dec/2025
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Regeneron Pharmaceuticals USD 898.6M 211.3M Dec/2025
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 1.7B 2.17B Dec/2025
Sanofi EUR 1.5B 2.29B Dec/2025
Sarepta Therapeutics USD -62.88M 178.46M Sep/2025
Teva Pharmaceutical Industries USD 487M 581M Dec/2025
Ultragenyx Pharmaceutical USD -114M 56.89M Dec/2025
United Therapeutics USD -14.6M 403.9M Dec/2025
Vertex Pharmaceuticals USD 1.26B 24.5M Dec/2025